SCHEMBL24200037

SCHEMBL24200037

COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CCl)cc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SENP1 Q9P0U3 2/20 0.43
AAK1 Q2M2I8 1/20 0.41
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
BACE1 P56817 2/20 0.37
CASP1 P29466 1/20 0.36
POLB P06746 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
BLM P54132 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PTPN1 P18031 1/20 0.35
HIF1A Q16665 1/20 0.35
ALDH1A1 P00352 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
ABL1 P00519 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL480638 0.91 SENP1 (0.43) SENP1AAK1KMT2AMEN1CTDSP1
SCHEMBL1116389 0.91 SENP1 (0.43) SENP1AAK1KMT2AMEN1CTDSP1
SCHEMBL31093996 0.91 SENP1 (0.43) SENP1AAK1KMT2AMEN1CTDSP1
SCHEMBL23037445 0.91 SENP1 (0.43) SENP1AAK1KMT2AMEN1CTDSP1
SCHEMBL480637 0.91 SENP1 (0.43) SENP1AAK1KMT2AMEN1CTDSP1
SCHEMBL437153 0.91 SENP1 (0.43) SENP1AAK1KMT2AMEN1CTDSP1
SCHEMBL3156965 0.91 SENP1 (0.41) SENP1AAK1KMT2AMEN1CTDSP1
SCHEMBL3156977 0.91 SENP1 (0.41) SENP1AAK1KMT2AMEN1CTDSP1
SCHEMBL3158303 0.90 SENP1 (0.42) SENP1AAK1KMT2AMEN1CTDSP1
SCHEMBL479541 0.90 SENP1 (0.42) SENP1AAK1KMT2AMEN1CTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105837493-A A synthetic method of Nintedanib and an intermediate of Nintedanib 东南大学 2016-08-10 CN claimed
US-20220127206-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-04-28 US disclosed
EP-3939954-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE Otsuka Pharmaceutical Co., Ltd. (JP) 2022-01-19 EP disclosed
CN-105837493-A A synthetic method of Nintedanib and an intermediate of Nintedanib 东南大学 2016-08-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127206-A1 METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE MGMT, FANCD2, ADAR SENP1 3584/4885AAK1 820/4885KMT2A 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.